T
43.57
-0.97 (-2.18%)
| Previous Close | 44.54 |
| Open | 43.80 |
| Volume | 293,579 |
| Avg. Volume (3M) | 631,858 |
| Market Cap | 1,672,094,592 |
| Price / Sales | 10.63 |
| Price / Book | 9.49 |
| 52 Weeks Range | |
| Earnings Date | 6 May 2025 - 12 May 2025 |
| Profit Margin | -63.16% |
| Operating Margin (TTM) | -36.77% |
| Diluted EPS (TTM) | -3.07 |
| Quarterly Revenue Growth (YOY) | 407.90% |
| Total Debt/Equity (MRQ) | 32.27% |
| Current Ratio (MRQ) | 4.43 |
| Operating Cash Flow (TTM) | -83.03 M |
| Levered Free Cash Flow (TTM) | -50.48 M |
| Return on Assets (TTM) | -23.46% |
| Return on Equity (TTM) | -54.83% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | Tarsus Pharmaceuticals, Inc. | Bullish | Bullish |
AIStockmoo Score
1.5
| Analyst Consensus | 4.0 |
| Insider Activity | -3.5 |
| Price Volatility | 2.0 |
| Technical Moving Averages | 1.0 |
| Technical Oscillators | 4.0 |
| Average | 1.50 |
|
Tarsus Pharmaceuticals Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of therapeutics, starting with eye care. It is focused on the development and commercialization of first-in-class therapeutic candidates to provide treatment for ophthalmic conditions. The company's candidate XDEMVY is a novel investigational eye drop to treat blepharitis caused by the infestation of Demodex mites, referred to as Demodex blepharitis. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 8.28% |
| % Held by Institutions | 103.10% |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 78.00 (Guggenheim, 79.02%) | Buy |
| Median | 72.00 (65.25%) | |
| Low | 58.00 (Jefferies, 33.12%) | Buy |
| Average | 68.20 (56.53%) | |
| Total | 5 Buy | |
| Avg. Price @ Call | 43.87 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| Jefferies | 06 Mar 2025 | 58.00 (33.12%) | Buy | 43.57 |
| Barclays | 26 Feb 2025 | 60.00 (37.71%) | Buy | 42.56 |
| 27 Jan 2025 | 62.00 (42.30%) | Buy | 51.45 | |
| Guggenheim | 26 Feb 2025 | 78.00 (79.02%) | Buy | 42.56 |
| HC Wainwright & Co. | 26 Feb 2025 | 73.00 (67.55%) | Buy | 42.56 |
| Oppenheimer | 22 Jan 2025 | 72.00 (65.25%) | Buy | 48.11 |
| Name | Avg. Buy ($) | Avg. Sell ($) | Net Quantity | Net Value ($) |
|---|---|---|---|---|
| AZAMIAN BOBAK R. | - | 49.50 | -30,216 | -1,493,032 |
| FARROW JEFFREY S | - | 48.54 | -3,724 | -180,611 |
| MOTTIWALA AZIZ | - | 48.54 | -10,565 | -512,394 |
| NEERVANNAN SESHADRI | - | 48.54 | -7,583 | -367,809 |
| WAHL BRYAN | - | 48.54 | -9,686 | -469,759 |
| WHITFIELD DIANNE C. | - | 48.54 | -6,711 | -325,475 |
| Aggregate Net Quantity | -68,485 | |||
| Aggregate Net Value ($) | -3,349,080 | |||
| Aggregate Avg. Buy ($) | - | |||
| Aggregate Avg. Sell ($) | 48.74 | |||
| Name | Holder | Date | Type | Quantity | Price | Value ($) |
|---|---|---|---|---|---|---|
| AZAMIAN BOBAK R. | Officer | 24 Mar 2025 | Automatic sell (-) | 6,000 | 52.36 | 314,160 |
| FARROW JEFFREY S | Officer | 20 Mar 2025 | Sell (-) | 1,186 | 49.91 | 59,193 |
| AZAMIAN BOBAK R. | Officer | 20 Mar 2025 | Sell (-) | 8,534 | 49.91 | 425,932 |
| WHITFIELD DIANNE C. | Officer | 20 Mar 2025 | Sell (-) | 2,137 | 49.91 | 106,658 |
| WAHL BRYAN | Officer | 20 Mar 2025 | Sell (-) | 3,084 | 49.91 | 153,922 |
| NEERVANNAN SESHADRI | Officer | 20 Mar 2025 | Sell (-) | 2,435 | 49.91 | 121,531 |
| MOTTIWALA AZIZ | Officer | 20 Mar 2025 | Sell (-) | 3,365 | 49.91 | 167,947 |
| FARROW JEFFREY S | Officer | 19 Mar 2025 | Sell (-) | 1,254 | 49.55 | 62,136 |
| AZAMIAN BOBAK R. | Officer | 19 Mar 2025 | Sell (-) | 8,551 | 49.55 | 423,702 |
| WHITFIELD DIANNE C. | Officer | 19 Mar 2025 | Sell (-) | 2,259 | 49.55 | 111,933 |
| WAHL BRYAN | Officer | 19 Mar 2025 | Sell (-) | 3,261 | 49.55 | 161,583 |
| NEERVANNAN SESHADRI | Officer | 19 Mar 2025 | Sell (-) | 2,543 | 49.55 | 126,006 |
| MOTTIWALA AZIZ | Officer | 19 Mar 2025 | Sell (-) | 3,557 | 49.55 | 176,249 |
| FARROW JEFFREY S | Officer | 18 Mar 2025 | Sell (-) | 1,284 | 46.17 | 59,282 |
| AZAMIAN BOBAK R. | Officer | 18 Mar 2025 | Sell (-) | 7,131 | 46.17 | 329,238 |
| WHITFIELD DIANNE C. | Officer | 18 Mar 2025 | Sell (-) | 2,315 | 46.17 | 106,884 |
| WAHL BRYAN | Officer | 18 Mar 2025 | Sell (-) | 3,341 | 46.17 | 154,254 |
| NEERVANNAN SESHADRI | Officer | 18 Mar 2025 | Sell (-) | 2,605 | 46.17 | 120,273 |
| MOTTIWALA AZIZ | Officer | 18 Mar 2025 | Sell (-) | 3,643 | 46.17 | 168,197 |
| Show more | ||||||
| Date | Type | Details |
|---|---|---|
| 12 Mar 2025 | Announcement | Tarsus Announces Proposed $100.0 Million Public Offering |
| 06 Mar 2025 | Announcement | Tarsus to Participate in Upcoming Investor Conference |
| 25 Feb 2025 | Announcement | Tarsus Reports Strong Fourth Quarter and Full-Year 2024 Financial Results and Recent Business Achievements |
| 20 Feb 2025 | Announcement | Tarsus to Report Fourth Quarter and Full-Year 2024 Financial Results on Tuesday, February 25, 2025 |
| 30 Jan 2025 | Announcement | Tarsus to Participate in Upcoming Investor Conferences |
| 13 Jan 2025 | Announcement | Tarsus Provides 2025 Update: Accelerating the Launch of XDEMVY® and Establishing Ocular Rosacea as the Next Category-Creating Opportunity in Eye Care |
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |